A Phase II Study to Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma as Second-line or Salvage Chemotherapy
Latest Information Update: 07 Jul 2023
At a glance
- Drugs Catequentinib (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms OASIS
- 06 Jun 2023 Status changed to recruiting, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 06 Jun 2023 Results (n=45) from gastric adenocarcinoma patients cohort reporting safety and efficacy presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Aug 2020 New trial record